<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: This study aimed to identify novel molecular markers for the early detection of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Genes related to <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">hepatic metastasis</z:e> were screened from the Oncomine database </plain></SENT>
<SENT sid="2" pm="."><plain>The candidate markers were tested by immunohistochemistry, and their predictive accuracy was assessed by the cross-validation method and an independent test set </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: We got three datasets containing 2,973 genes that were highly expressed in primary <z:hpo ids='HP_0003003'>colon cancer</z:hpo> tissues compared with non-metastatic <z:hpo ids='HP_0003003'>colon cancer</z:hpo> tissues and identified 7 candidate molecules for immunohistochemical validation </plain></SENT>
<SENT sid="4" pm="."><plain>A total of 213 colorectal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> samples were randomly divided into a training set (113 cases) and a blind testing set (100 cases) </plain></SENT>
<SENT sid="5" pm="."><plain>In the training set, immunohistochemical analysis showed that HP, OPN, and PTGIS expression were significantly higher in the <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">hepatic metastasis</z:e> group than in the non-<z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> group </plain></SENT>
<SENT sid="6" pm="."><plain>Logistic regression analysis showed that HP and OPN levels in <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> and lymph node <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> status were the only significant (P&lt;0.05) parameters for detecting <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>The predictive accuracy of markers was assessed by the cross-validation method and an independent test set </plain></SENT>
<SENT sid="8" pm="."><plain>In leave-one-out cross-validation, the two markers combined with clinicopathologic features resulted in 91.2% sensitivity and 96.4% specificity for <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">hepatic metastasis</z:e> detection </plain></SENT>
<SENT sid="9" pm="."><plain>In an independent test set, the combination achieved 94.5% sensitivity and 88.9% specificity for predicting the <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">hepatic metastasis</z:e> of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Our results suggest that combined HP and OPN expression levels are significantly related to <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> and prognosis, and, if this is validated, they could be used as accurate predictors of <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>